Couvineau A, Laburthe M
J Clin Endocrinol Metab. 1985 Jul;61(1):50-5. doi: 10.1210/jcem-61-1-50.
To characterize the molecular components of the vasoactive intestinal peptide (VIP) receptor in human intestine, [125I]VIP was covalently bound to human colonic epithelial membranes using dithio-bis(succinimidyl propionate). Sodium dodecyl sulfate-polyacrylamide gel autoradiographic studies of affinity labeled membranes revealed three major bands corresponding to [125I]VIP-protein complexes of 66,000, 33,000, and 16,000 mol wt. Labeling of the 66,000 and 33,000 mol wt complexes was specific, since it was abolished by VIP, while labeling of the 16,000 mol wt complex was not. Densitometric scanning of autoradiographs indicated that labeling of the 66,000 mol wt complex was inhibited by low VIP concentrations in the 10(-10)-10(-8) M range, but was unaffected by glucagon or octa-cholecystokinin. It was also reduced by VIP-(2-28), with a potency 1/100th that of VIP, and by GTP in the concentration range of 10(-7)-10(-3) M. The 33,000 mol wt complex behaved similarly to the 66,000 mol wt complex with respect to specificity and GTP sensitivity, but differed in one major feature, its affinity for VIP. Its labeling was inhibited by native VIP concentrations in the 10(-9)-10(-7) M range. Assuming one molecule of [125I]VIP bound per molecule of protein, two proteins of 63,000 and 30,000 mol wt were identified as VIP-binding sites. The 63,000 mol wt protein had the properties expected for the VIP receptor coupled to adenylate cyclase in human colon, while the 30,000 mol wt protein was a low affinity binding site. Treatment of human colonic membranes with the sulfhydryl reducing agent dithiothreitol before [125I]VIP binding strongly reduced the labeling of the two proteins. This finding does not support the hypothesis that the low affinity 30,000 mol wt binding site may be a monomer of the high affinity binding site.
为了鉴定人肠道中血管活性肠肽(VIP)受体的分子成分,使用二硫代双(琥珀酰亚胺丙酸酯)将[125I]VIP共价结合到人结肠上皮细胞膜上。对亲和标记膜进行十二烷基硫酸钠-聚丙烯酰胺凝胶放射自显影研究,结果显示有三条主要条带,分别对应分子量为66,000、33,000和16,000的[125I]VIP-蛋白质复合物。分子量为66,000和33,000复合物的标记具有特异性,因为VIP可将其消除,而分子量为16,000复合物的标记则不受影响。对放射自显影片进行光密度扫描表明,分子量为66,000复合物的标记在10(-10)-10(-8)M范围内会受到低浓度VIP的抑制,但不受胰高血糖素或八肽胆囊收缩素的影响。它也会被VIP-(2-28)(其效力为VIP的1/100)以及浓度在10(-7)-10(-3)M范围内的GTP所降低。分子量为33,000的复合物在特异性和对GTP的敏感性方面与分子量为66,000的复合物表现相似,但在一个主要特征上有所不同,即它对VIP的亲和力。其标记在10(-9)-10(-7)M范围内的天然VIP浓度下会受到抑制。假设每个蛋白质分子结合一分子[125I]VIP,则鉴定出两种分子量分别为63,000和30,000的蛋白质为VIP结合位点。分子量为63,000的蛋白质具有人结肠中与腺苷酸环化酶偶联的VIP受体所预期的特性,而分子量为30,000的蛋白质是一个低亲和力结合位点。在进行[125I]VIP结合之前,用巯基还原剂二硫苏糖醇处理人结肠膜,会强烈降低这两种蛋白质的标记。这一发现不支持低亲和力的分子量为30,000的结合位点可能是高亲和力结合位点单体的假说。